Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study
Levosimendan is used for the short-term treatment of severe heart failure or other cardiac conditions. The area of existing clinical applications for levosimendan has increased significantly. This study aimed to assess whether levosimendan and its metabolites impact the mechanisms related to platele...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/3/1824 |
| _version_ | 1797318633676865536 |
|---|---|
| author | Joanna Sikora Krzysztof Pstrągowski Aleksandra Karczmarska-Wódzka Patrycja Wszelaki Katarzyna Buszko Zbigniew Włodarczyk |
| author_facet | Joanna Sikora Krzysztof Pstrągowski Aleksandra Karczmarska-Wódzka Patrycja Wszelaki Katarzyna Buszko Zbigniew Włodarczyk |
| author_sort | Joanna Sikora |
| collection | DOAJ |
| description | Levosimendan is used for the short-term treatment of severe heart failure or other cardiac conditions. The area of existing clinical applications for levosimendan has increased significantly. This study aimed to assess whether levosimendan and its metabolites impact the mechanisms related to platelet activation. In this study, we included patients with coronary artery disease receiving antiplatelet therapy. We analyzed the pharmacodynamic profile using three independent methods to assess platelet activity. The results of the conducted studies indicate a mechanism of levosimendan that affects the function of platelets, causing higher inhibition of platelet receptors and, thus, their aggregation. It is essential to clarify whether levosimendan may affect platelets due to the need to maintain a balance between bleeding and thrombosis in patients treated with levosimendan. This is especially important in the case of perioperative bleeding. This study was conducted in vitro; the research should be continued and carried out in patients to check the complete pharmacokinetic and pharmacodynamic profile. |
| first_indexed | 2024-03-08T03:55:10Z |
| format | Article |
| id | doaj.art-f70e08957128462bb32cc4c41bee871f |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T03:55:10Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-f70e08957128462bb32cc4c41bee871f2024-02-09T15:14:46ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-02-01253182410.3390/ijms25031824Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot StudyJoanna Sikora0Krzysztof Pstrągowski1Aleksandra Karczmarska-Wódzka2Patrycja Wszelaki3Katarzyna Buszko4Zbigniew Włodarczyk5Research and Education Unit for Experimental Biotechnology, Department of Transplantology and General Surgery, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandDepartment of Cardiology and Internal Medicine, Antoni Jurasz University Hospital No. 1 in Bydgoszcz, 85-094 Bydgoszcz, PolandResearch and Education Unit for Experimental Biotechnology, Department of Transplantology and General Surgery, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandResearch and Education Unit for Experimental Biotechnology, Department of Transplantology and General Surgery, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandDepartment of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandDepartment of Transplantology and General Surgery, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandLevosimendan is used for the short-term treatment of severe heart failure or other cardiac conditions. The area of existing clinical applications for levosimendan has increased significantly. This study aimed to assess whether levosimendan and its metabolites impact the mechanisms related to platelet activation. In this study, we included patients with coronary artery disease receiving antiplatelet therapy. We analyzed the pharmacodynamic profile using three independent methods to assess platelet activity. The results of the conducted studies indicate a mechanism of levosimendan that affects the function of platelets, causing higher inhibition of platelet receptors and, thus, their aggregation. It is essential to clarify whether levosimendan may affect platelets due to the need to maintain a balance between bleeding and thrombosis in patients treated with levosimendan. This is especially important in the case of perioperative bleeding. This study was conducted in vitro; the research should be continued and carried out in patients to check the complete pharmacokinetic and pharmacodynamic profile.https://www.mdpi.com/1422-0067/25/3/1824plateletsADPlevosimendanaggregationantiplatelet therapy |
| spellingShingle | Joanna Sikora Krzysztof Pstrągowski Aleksandra Karczmarska-Wódzka Patrycja Wszelaki Katarzyna Buszko Zbigniew Włodarczyk Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study International Journal of Molecular Sciences platelets ADP levosimendan aggregation antiplatelet therapy |
| title | Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study |
| title_full | Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study |
| title_fullStr | Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study |
| title_full_unstemmed | Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study |
| title_short | Impact of Levosimendan and Its Metabolites on Platelet Activation Mechanisms in Patients during Antiplatelet Therapy—Pilot Study |
| title_sort | impact of levosimendan and its metabolites on platelet activation mechanisms in patients during antiplatelet therapy pilot study |
| topic | platelets ADP levosimendan aggregation antiplatelet therapy |
| url | https://www.mdpi.com/1422-0067/25/3/1824 |
| work_keys_str_mv | AT joannasikora impactoflevosimendananditsmetabolitesonplateletactivationmechanismsinpatientsduringantiplatelettherapypilotstudy AT krzysztofpstragowski impactoflevosimendananditsmetabolitesonplateletactivationmechanismsinpatientsduringantiplatelettherapypilotstudy AT aleksandrakarczmarskawodzka impactoflevosimendananditsmetabolitesonplateletactivationmechanismsinpatientsduringantiplatelettherapypilotstudy AT patrycjawszelaki impactoflevosimendananditsmetabolitesonplateletactivationmechanismsinpatientsduringantiplatelettherapypilotstudy AT katarzynabuszko impactoflevosimendananditsmetabolitesonplateletactivationmechanismsinpatientsduringantiplatelettherapypilotstudy AT zbigniewwłodarczyk impactoflevosimendananditsmetabolitesonplateletactivationmechanismsinpatientsduringantiplatelettherapypilotstudy |